Retatrutide: the triple agonist redefining obesity research (Guide 2026)

Quick summary

• What it is: an experimental peptide from Eli Lilly (code LY3437943) that simultaneously activates three hormonal receptors: GIP, GLP-1, and glucagon.
• Evidence: a very comprehensive clinical program, with published phase 2 trials and four phase 3 trials (TRIUMPH) with results reported in 2025 and 2026.
• Results: the largest average weight losses reported so far for an injectable obesity drug.
• Regulatory status (October 2026): not approved in any country. Lilly expects to file for FDA approval in the first quarter of 2027.

---

What is retatrutide?

Retatrutide is a long-acting synthetic peptide designed for once-weekly administration. It belongs to the incretin-based drug family — the same as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — but with one key difference: it acts on three targets instead of one or two.

That is why it is sometimes informally called "triple G" or even "GLP-3," although the latter name is not technical.

Three-generation evolution

---

How it works: three hormones, three functions

Each receptor contributes a distinct effect:

• GLP-1: reduces appetite by acting on the brain, slows gastric emptying, and improves insulin release when glucose rises.
• GIP: enhances insulin secretion and appears to complement the GLP-1 effect on weight and tolerance.
• Glucagon: this is the novel part. Activating the glucagon receptor increases energy expenditure and promotes fat use, especially in the liver.

This may seem counterintuitive, since glucagon tends to raise blood glucose. The design rationale is that GLP-1 and GIP effects compensate for that rise, while the increased energy expenditure and hepatic fat reduction from glucagon are captured. The balance between the three receptors was deliberately tuned during molecule design, as described in the discovery paper by Coskun et al. (2022).

---

Phase 2: the first data that attracted attention

Obesity without diabetes (Jastreboff et al., 2023)

Published in The New England Journal of Medicine, this randomized, double-blind, placebo-controlled trial enrolled adults with obesity or overweight without diabetes:

• At 24 weeks (primary endpoint), the highest dose achieved a mean weight loss of 17.5%.
• At 48 weeks, that same dose reached 24.2%, vs 2.1% with placebo.
• The response showed a clear dose-response relationship: higher dose, greater weight loss.
• A dose-dependent increase in heart rate was observed, peaking around week 24 and then declining.

Type 2 diabetes (Rosenstock et al., 2023)

Published in The Lancet, showing improvements in glucose control and weight in people with type 2 diabetes.

Liver fat

In a subanalysis of the obesity trial, around 80% of participants with excess hepatic fat at baseline normalized it by week 24 with the highest doses. This explains why retatrutide is also being investigated in fatty liver disease (MASLD/MASH).

---

Phase 3: the TRIUMPH program

Between December 2025 and July 2026, Lilly reported results from the four large phase 3 trials of the TRIUMPH program. All met their primary endpoints.

Key TRIUMPH-1 data:

• 45.3% of participants on the highest dose lost at least 30% of body weight — a magnitude previously associated with bariatric surgery.
• In a two-year extension in participants with severe obesity, mean weight loss reached 30.3%.

For context: in the tirzepatide reference trial (SURMOUNT-1), mean weight loss with the highest dose was around 21% at 72 weeks. Cross-trial comparisons should be made with caution, as populations and designs are not identical.

Important: TRIUMPH-1, 3, and 4 results have been communicated primarily through press releases and conference presentations. Full data review will come with scientific publications and regulatory agency evaluation.

---

Safety: what is known

The adverse effect profile is broadly similar to other drugs in this family, with some nuances:

• Gastrointestinal effects (nausea, vomiting, diarrhea, constipation): most common, especially during dose escalation.
• Heart rate: dose-dependent increase, already observed in phase 2.
• Dysesthesia: sensory disturbances in the skin were described in phase 3, less common in other drugs in this family and worth monitoring.
• Discontinuation due to adverse effects: varied by trial and dose. In TRIUMPH-3, for example, it was 9.8% and 13.5% for the two doses studied, vs 4.8% with placebo.

What is not yet known: very long-term effects, the impact on major cardiovascular events (heart attack, stroke), and how it behaves outside the controlled trial environment. The glucagon receptor activity raises its own questions that the regulatory evaluation will need to address.

---

Regulatory status (updated October 2026)

Approval: retatrutide is not approved in any country. Lilly has announced it will file a Biologics License Application (BLA) with the FDA in the first quarter of 2027, after completing the manufacturing dossier. If approved, it is expected to reach the US market in late 2027 or 2028. In the European Union it is not authorized.

Current legal access: only through clinical trials or the pre-approval expanded access program Lilly registered in 2026.

Actions against unauthorized sale:

• In June 2026, the FDA expressly warned that retatrutide cannot be marketed or prepared in compounding pharmacies, and identified as illegal products falsely labeled "for research" or "not for human consumption."
• In August 2026, Lilly sued six US companies for selling retatrutide, several under the "research use" label, and has reported more than 14,000 websites, ads, and posts in over 100 countries.
• In the UK, the MHRA has seized counterfeit pre-filled pens, some containing substances other than those declared, such as insulin.

Sport (WADA): as a substance without therapeutic approval for human use, it falls under category S0 of the Prohibited List.

---

Conclusion

Retatrutide is probably the most promising molecule in current obesity research: an innovative triple-receptor design, a comprehensive phase 3 program, and weight loss results approaching those of surgery. Its glucagon component also opens research lines in fatty liver and energy expenditure.

At the same time, it remains an investigational drug: unapproved, with long-term safety data pending, and a regulatory review that will not begin until 2027. Enormous demand has generated a market of unauthorized and counterfeit products that agencies and the manufacturer are actively pursuing.

---

Frequently asked questions

What is the difference between retatrutide, tirzepatide, and semaglutide? Semaglutide activates one receptor (GLP-1), tirzepatide two (GLP-1 and GIP), and retatrutide three (GLP-1, GIP, and glucagon). The glucagon receptor adds increased energy expenditure and hepatic fat reduction.

Is it approved? No, in any country. Lilly expects to apply for FDA approval in early 2027.

How much weight was lost in the trials? In the main phase 3 trial (TRIUMPH-1), mean weight loss with the highest dose was 28.3% at 80 weeks, vs 2.2% with placebo. In people with diabetes or cardiovascular disease it was somewhat lower (20.8% and 22.6%).

What are the side effects? Primarily gastrointestinal (nausea, vomiting, diarrhea), increased heart rate, and in some participants, skin sensory disturbances. Long-term effects are still being evaluated.

Is it legal to buy? No authorized product exists. The FDA and MHRA have warned that products sold as "for research" are not legal for consumption and may be counterfeit or contain other substances.

---

References

1. Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022.
2. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514-26. DOI 10.1056/NEJMoa2301972
3. Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023.
4. Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1). Press release, May 21, 2026. investor.lilly.com
5. Eli Lilly and Company. Retatrutide successful in two additional Phase 3 obesity trials (TRIUMPH-2 and TRIUMPH-3). Press release, July 23, 2026. prnewswire.com
6. ClinicalTrials.gov. NCT05929079 — TRIUMPH-2. View record
7. ClinicalTrials.gov. NCT05882045 — TRIUMPH-3. View record
8. ClinicalTrials.gov. NCT07629401 — Pre-approval expanded access of retatrutide. View record
9. Healio. Eli Lilly files lawsuits against six companies for allegedly selling retatrutide. August 2026. healio.com
10. World Anti-Doping Agency (WADA). 2026 Prohibited List, category S0. wada-ama.org